Hepatocellular carcinoma (HCC) is the most common liver malignancy worldwide and a major cause of cancer-related mortality for which liver resection is an important curative-intent treatment option. However, many patients present with advanced disease and with underlying chronic liver disease and/or cirrhosis, limiting the proportion of patients who are surgical candidates. In addition, the development of recurrent or de novo cancers following surgical resection is common. These issues have led investigators to evaluate the benefit of neoadjuvant and adjuvant treatment strategies aimed at improving resectability rates and decreasing recurrence rates. While high-level evidence to guide treatment decision making is lacking, recent advances in locoregional and systemic therapies, including antiviral treatment and immunotherapy, raise the prospect of novel approaches that may improve the outcomes of patients with HCC. In this review, we evaluate the evidence for various neoadjuvant and adjuvant therapies and discuss opportunities for future clinical and translational research.

No abstract

One third of patients with decompensated cirrhosis are readmitted within 30 days of discharge. The use of simple risk scoring model with high generalizability, based on demographics, clinical features and interventions can bring refinement to the prediction of 30-day readmission in high risk patients. Mumtaz readmission risk score highlights the need for targeted interventions in order to decrease rates of readmission within this population. This article is protected by copyright. All rights reserved.

No abstract